LM

LMAT

$78.80
Sharia status
NOT DETERMINED
Our own screen rated every one of the seven published methodologies and none passed, while our secondary compliance provider rates it compliant — we will not publish either as a verdict
HTR non-permissible income 5.25%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.
Why this signal?
Structure2 of 5 timeframes bullish · 47.8% aligned
VWAPPrice below VWAP ($79.91)
VolumeRelative volume 3.1× the 20-day average
Momentum10-day rate of change -1.2%

Lemaitre Vascular Inc (LMAT) was screened and our screen declined to rate it, so we publish no verdict, per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.

Market & analysts
Wall Street consensus
BUY
14 analysts
Price target
$107.00
+35.8% · 7 analysts
Institutional own.
103.8% *
of shares
Momentum (10d)
-1.2%
rate of change
SMC grade
C · 57
47.8% aligned
NOT-DETERMINED
Sharia compliance
5.25%
Non-permissible income — HTR, from filings (2025-12-31)
C · 57
SMC grade — 47.8% timeframe alignment
-1.2%
Rate of change (10d)
BUY
Wall Street consensus (14)
$107.00
Price target (+35.8%) · 7 analysts
103.8%
Institutional ownership *

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for LMAT — this runs off the critical path so the page paints first. It will appear here on its own.

116.75107.2597.7688.2678.762025-09-112026-03-122026-09-10

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
77.15
S2
77.74
S1
78.61
PIVOT
79.20
R1
80.07
R2
80.66
R3
81.53

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
74.9947 85.9853
±6.83% from 80.49, made 2026-09-04 · resolves 2026-09-11
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 21812 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
4 buy · 1 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)35.10NEUTRAL
Stochastic %K (14)11.04BUY
CCI (20)-105.01BUY
Williams %R (14)-88.96BUY
MACD (12,26,9)0.46BUY
ROC (10)-1.02SELL
Momentum (10)-0.81SELL
EMA (10)80.18SELL
SMA (10)80.22SELL
EMA (20)81.92SELL
SMA (20)80.80SELL
EMA (30)84.00SELL
SMA (30)83.79SELL
EMA (50)87.40SELL
SMA (50)90.54SELL
EMA (100)91.72SELL
SMA (100)95.13SELL
EMA (200)91.89SELL
SMA (200)94.38SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Lemaitre Vascular Inc

Healthcare · Medical Instruments & Supplies

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

lemaitre.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 62
⏰ 4H BULLISH 32
🕐 1H BULLISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BEARISH 234

Momentum & Volume

-2.71
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.